Gilead Sciences Inc. (GILD)
What To Expect From Gilead In Q3 2025
Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On October 23, Gilead announced that it will announce data on the switching of people with PBC from obeticholic acid to its 'rising star' Livdelzi at The Liver Meeting 2025.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead's Trodelvy cuts breast cancer risk by 38% in trial
Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
Gilead Sciences (GILD) is a top-performing healthcare stock in 2025, up 36% YTD and breaking out to all-time highs. GILD's strong Q2 results, raised guidance, and robust HIV portfolio drive optimism, with FDA approval and delayed Biktarvy exclusivity boosting long-term prospects. Valuation remains attractive, with technical analysis signaling potential upside to $150 in the near term and $185 longer term.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
Resurfaced tensions between the U.S. and China caught the market off guard in Friday's trading session, with the S&P 500 and Nasdaq falling over 2% on news that President Trump plans to impose an additional 100% tariff on Chinese goods starting November 1st.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
